- Company
- Vabysmo pays attention to entry into reimbursement
- by Eo, Yun-Ho Aug 18, 2023 05:20am
- Vabysmo, a treatment for macular degeneration, stood in front of the final gateway to being listed as an insurance benefit. According to industry sources, Roche Korea's first bispecific antibody treatment Vabysmo for the ophthalmic disease is in negotiations with NHIS. Last month (July), this drug accepted the conditions below the evaluation
- Company
- Bavencio’s reimb may change the Rx paradigm in KOR
- by Hwang, byoung-woo Aug 17, 2023 05:29am
- Changes are arising in the prescription pattern for metastatic urothelial cancer due to the emergence of new treatment options. The reimbursement of Bavencio (avelumab) as a first-line maintenance therapy, increased treatment options for the patients. The drug was first granted reimbursement only as a second-line treatment. As demand for m
- Company
- Retevmo fails reimb at the last stage in KOR
- by Eo, Yun-Ho Aug 17, 2023 05:29am
- The RET-targeted anticancer therapy ‘Retevmo’ failed to pass the last gateway to reimbursement listing in Korea. According to industry sources, the drug pricing negotiations between the National Health Insurance Service and Lilly Korea for the reimbursement of the RET inhibitor Retevmo (selpercatinib) broke down recently. Retevmo,
- Company
- Companies seek to invalidate Jardiance’s unlisted patents
- by Kim, Jin-Gu Aug 16, 2023 05:37am
- Generic companies have begun challenging the unlisted patent of Jardiance (empagliflozin), an SGLT-2 inhibitor-class diabetes treatment. From the generic companies’ perspective, they must overcome Jardiance’s unlisted patents to release their generics early, just after Jardiance’s substance patent expires in 2025. According to industry
- Company
- [Reporter’s View] Trending CSO sales and their treatment
- by Lee, Seok-Jun Aug 16, 2023 05:37am
- Contract sales organizations (CSOs) are trending in the pharmaceutical industry. The Ministry of Food and Drug Safety announced that 45% of the 195 companies it had surveyed use CSO companies. When limiting the subjects to small-to-mid-size companies, the industry expects the rate to far exceed 70%. The Top 10 pharmaceutical companies in Kor
- Company
- Cinqair draws attention to entry into reimbursement rights
- by Eo, Yun-Ho Aug 16, 2023 05:37am
- Attention is focusing on whether Cinqair, an asthma antibody drug, will be listed on the list of insurance benefits after six years of domestic approval. According to related industries, Teva Handok is negotiating with the NHIS for the listing of Cinqair, a monoclonal antibody targeting interleukin (IL)-5. Unlike competitive drugs, positive
- Company
- the era of Lung cancer cure
- by Jung, Sae-Im Aug 14, 2023 05:21am
- The third-generation EGFR-targeting anti-cancer drug Tagrisso (Osimertinib) has left a unique record in non-small cell lung cancer. Significant improvement was achieved in adjuvant therapy after surgery, and it was also proven that survival time could be extended. This is an area that previous TKI drugs have failed to overcome. Tagrisso has alre
- Company
- First immuno-oncology drug for endometrial cancer?
- by Eo, Yun-Ho Aug 14, 2023 05:21am
- Attention is rising on whether the first immuno-onoclogy treatment option will be approved for endometrial cancer in Korea. According to industry sources, GSK Korea’s PD-1 inhibitor Jemperli (dostarlimab) has passed review by the Health Insurance Review and Assessment Service’s Drug Reimbursement Evaluation Committee and is soon to sta
- Company
- With the BPH drug Duodart be the first combo to succeed?
- by Kim, Jin-Gu Aug 14, 2023 05:21am
- GSK’s benign prostatic hyperplasia (BPH) drug ‘Duodart (dutasteride+tamsulosin)’ has been making rapid growth in the outpatient prescription market in Korea. Until now, the market for combination drugs in the field of urology was considered barren. Unlike other chronic disease areas, combination drugs are rare in the area. Companies ha
- Company
- Oral SMA drug Evrysdi prescribed at tertiary hospitals
- by Eo, Yun-Ho Aug 14, 2023 05:21am
- The oral spinal muscular atrophy (SMA) treatment ‘Evrysdi’ may now be prescribed at tertiary hospitals in Korea. According to industry sources, Roche Korea’s SMA treatment Evrysdi (risdiplam) passed the drug committee (DC) reviews at the Big 5 tertiary hospitals in Korea - Samsung Medical Center, Seoul National University Hospital, Seou
